Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Buy rating on PROCEPT BioRobotics (NASDAQ:PRCT) and increased the price target from $48 to $50.
December 22, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter reaffirmed a Buy rating on PROCEPT BioRobotics and raised the price target to $50, indicating a positive outlook on the stock.
The increase in price target by Truist Securities suggests a bullish outlook on PROCEPT BioRobotics, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100